PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY ADULT MALE SUBJECTS

被引：0
|
作者：
Gillen, M. [1 ]
Shen, Z. [2 ]
Miner, J. N. [2 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Ardea Biosci Inc, San Diego, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5133
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0886
引用
收藏
页码：1366 / 1366
页数：1
相关论文
共 50 条
  • [11] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    Smith, William B.
    Hall, Jesse
    Berg, Jolene K.
    Kazimir, Michal
    Yamamoto, Amy
    Walker, Susan
    Lee, Caroline A.
    Shen, Zancong
    Wilson, David M.
    Zhou, Dongmei
    Gillen, Michael
    Marbury, Thomas C.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 703 - 713
  • [12] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    William B. Smith
    Jesse Hall
    Jolene K. Berg
    Michal Kazimir
    Amy Yamamoto
    Susan Walker
    Caroline A. Lee
    Zancong Shen
    David M. Wilson
    Dongmei Zhou
    Michael Gillen
    Thomas C. Marbury
    Clinical Drug Investigation, 2018, 38 : 703 - 713
  • [13] Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
    Shen, Zancong
    Rowlings, Colin
    Kerr, Brad
    Hingorani, Vijay
    Manhard, Kimberly
    Quart, Barry
    Yeh, Li-Tain
    Storgard, Chris
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3423 - 3434
  • [14] PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF VERINURAD (RDEA3170) IN ADULT MALE SUBJECTS WITH MILD, MODERATE, AND SEVERE RENAL IMPAIRMENT: A PHASE 1, OPEN-LABEL STUDY
    Smith, W. B.
    Hall, J.
    Berg, J. K.
    Kazimir, M.
    Yamamoto, A.
    Walker, S.
    Lee, C.
    Marbury, T. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 371 - 371
  • [15] Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
    Hall, Jesse
    Gillen, Michael
    Yang, Xiaojuan
    Shen, Zancong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 179 - 187
  • [16] PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VERINURAD (RDEA3170) IN COMBINATION WITH FEBUXOSTAT VERSUS FEBUXOSTAT ALONE AND VERINURAD ALONE IN JAPANESE ADULTS WITH GOUT OR ASYMPTOMATIC HYPERURICEMIA: A PHASE 2A, OPEN-LABEL STUDY
    Shiramoto, M.
    Liu, S.
    Shen, Z.
    Hall, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 371 - 372
  • [17] Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
    Li, Zhaoyang
    Radin, Allen
    Li, Meng
    Hamilton, Jennifer D.
    Kajiwara, Miyuki
    Davis, John D.
    Takahashi, Yoshinori
    Hasegawa, Setsuo
    Ming, Jeffrey E.
    DiCioccio, A. Thomas
    Li, Yongtao
    Kovalenko, Pavel
    Lu, Qiang
    Ortemann-Renon, Catherine
    Ardeleanu, Marius
    Swanson, Brian N.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (06): : 742 - 755
  • [18] Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during the first administration to healthy male subjects
    Nunes, T.
    Rocha, J. -F.
    Pinto, R.
    Machado, R.
    Wright, L.
    Falcao, A.
    Almeida, L.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 302 - 302
  • [19] The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Stangier, Joachim
    Rathgen, Karin
    Staehle, Hildegard
    Gansser, Dietmar
    Roth, Willy
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) : 292 - 303
  • [20] Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects
    Yamahira, Naomi
    Frost, Charles
    Fukase, Hiroyuki
    Yu, Zhigang
    Wang, Jessie
    Pursley, Janice
    LaCreta, Frank
    Hiraoka, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) : 564 - 573
12345